DAX21.506 +0,4%ESt505.265 +0,9%Top 10 Crypto15,30 -4,1%Dow44.484 +0,1%Nas19.589 +1,0%Bitcoin95.625 -2,7%Euro1,0374 +0,3%Öl76,37 +1,2%Gold2.842 +1,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Palantir A2QA4J Rheinmetall 703000 Infineon 623100 Tesla A1CX3T Siemens Energy ENER6Y PayPal A14R7U Volkswagen (VW) vz. 766403 Amazon 906866 Deutsche Telekom 555750 Deutsche Bank 514000 Mercedes-Benz Group (ex Daimler) 710000 Bayer BAY001 Apple 865985 Microsoft 870747
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Zollbeben hält an: DAX schließt fester -- Palantir mit Gewinnsprung -- PayPal-Gewinn enttäuscht -- Infineon übertrifft Erwartungen -- Merck, SAP, Rheinmetall, TUI, D-Wave im Fokus
Top News
NASDAQ Composite aktuell: NASDAQ Composite am Dienstagmittag mit Gewinnen NASDAQ Composite aktuell: NASDAQ Composite am Dienstagmittag mit Gewinnen
Starker Wochentag in New York: NASDAQ 100 zeigt sich am Dienstagmittag fester Starker Wochentag in New York: NASDAQ 100 zeigt sich am Dienstagmittag fester
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

INNATE PHARMA SA Aktie

NeuKaufenVerkaufen
1,91 EUR +0,20 EUR +11,54 %
STU
1,77 EUR -0,03 EUR -1,89 %
PAR
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.148,01 Mio. EUR

Div. Rendite0,00%

WKNA0LCUJ

ISINFR0010331421

SymbolIPHYF

INNATE PHARMA SA Aktien News

DatumMeistgelesen
BusinesswireInnate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
BusinesswireInnate Pharma Announces Its Participation to Upcoming Investor Conference
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of January 1, 2024
BusinesswireInnate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
BusinesswireInnate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
BusinesswireInnate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
BusinesswireInnate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
BusinesswireInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
BusinesswireInnate Pharma to Host Virtual KOL Event on Lacutamab
BusinesswireInnate Pharma Reports Third Quarter 2023 Financial Results and Business Update
BusinesswireInnate Pharma Announces Conference Call for Third Quarter 2023 Business Update
BusinesswireInnate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023
BusinesswireInnate Pharma Announces Its Participation to Upcoming Investor Conferences
BusinesswireInnate Pharma 2024 Financial Calendar
BusinesswireInnate Pharma Announces Abstracts Selected for ESMO Congress 2023
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of October 3, 2023
BusinesswireInnate Pharma Provides Update on Lacutamab Clinical Program
BusinesswireInnate Pharma Reports First Half 2023 Financial Results and Business Update
BusinesswireInnate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update
BusinesswireInnate Pharma to Participate in Upcoming Investor Conference
BusinesswireFirst Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of July 1, 2023
BusinesswireFirst Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
BusinesswireInnate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
BusinesswireInnate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
BusinesswireInnate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
BusinesswireSAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of June 1, 2023
BusinesswireInnate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
BusinesswireInnate Pharma to Participate in Upcoming Investor Conferences
BusinesswireInnate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress
BusinesswireOutcome of Innate Pharma’s 2023 Annual General Meeting
finanzen.netINNATE PHARMA SA präsentierte das Zahlenwerk zum abgelaufenen Jahresviertel
BusinesswireInnate Pharma Reports First Quarter 2023 Financial Results and Business Update
BusinesswireNumber of shares and voting rights of Innate Pharma as of May 1, 2023
BusinesswireInnate Pharma Announces Conference Call and Webcast for Q1 Business Update
BusinesswireInnate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting
BusinesswireInnate Pharma Establishes a New At-The-Market ("ATM”) Program on Nasdaq
BusinesswireInnate Pharma to Participate in Upcoming Investor Conference
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of April 1, 2023
Wer­bung

INNATE PHARMA SA News

INNATE PHARMA SA News: auf dieser Seite finden Sie alle INNATE PHARMA SA News und Nachrichten zur INNATE PHARMA SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch INNATE PHARMA SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um INNATE PHARMA SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.